In view of the concordance of our results with the recent literature, it seems that BCR may be suspected and may lead to PSMA-11 PET/CT at lower sPSAs than currently recommended [24, 25], to early detect limited recurrence of PC that may respond to locally targeted therapy. This evidence concerns the gene BCR and pachyonychia congenita.